Table 5.

Median duration (in days) of select adverse events within the subset of patients who experienced those events^a.

	Courses 1, 3, or 5 (with GM-CSF) (n = 104)		Courses 2 or 4 (with IL-2) (n = 100)		Anytime on treatment
Toxicities	N with toxicity	Median duration (days)	N with toxicity	Median duration (days)	N with toxicity	Median duration (days)
Neuropathic pain	54	2.0	38	2.0	64	2.5
Ocular toxicitiescb	14	3.5	6	69.0	19	5.0
Anatomical paind	54	2.0	39	2.0	64	3.0
Capillary leak syndrome	1	2.0	6	2.5	7	2.0
Allergic reaction	8	1.5	13	2.0	17	2.0
Hypertension	1	238.0	2	7.0	3	13.0
Fever	28	1.0	63	2.0	70	2.0

^aFor a given adverse event, the longest duration of an event was selected per patient per treatment course. Only Grades 3–4 were used in calculations unless otherwise specified (the Grade 5 cardiac arrest has been excluded from this table).

^bOne ocular toxicity was ongoing and had no date of resolution. This record is omitted from calculations.

^cAll grades were used for calculations.

^dSee Table S1 in Supplementary Material for the description of anatomical pain.